نتایج جستجو برای: bevacizumab

تعداد نتایج: 11192  

2015
Ji Liang Yuji Piao Verlene Henry Ningyi Tiao John F. de Groot

PURPOSE Antiangiogenic therapy is commonly being used for the treatment of glioblastoma. However, the benefits of angiogenesis inhibitors are typically transient and resistance often develops. Determining the mechanism of treatment failure of the VEGF monoclonal antibody bevacizumab for malignant glioma would provide insight into approaches to overcome therapeutic resistance. EXPERIMENTAL DES...

Journal: :The Lancet. Oncology 2012
Aimery de Gramont Eric Van Cutsem Hans-Joachim Schmoll Josep Tabernero Stephen Clarke Malcolm J Moore David Cunningham Thomas H Cartwright J Randolph Hecht Fernando Rivera Seock-Ah Im György Bodoky Ramon Salazar Frédérique Maindrault-Goebel Einat Shacham-Shmueli Emilio Bajetta Martina Makrutzki Aijing Shang Thierry André Paulo M Hoff

BACKGROUND Bevacizumab improves the efficacy of oxaliplatin-based chemotherapy in metastatic colorectal cancer. Our aim was to assess the use of bevacizumab in combination with oxaliplatin-based chemotherapy in the adjuvant treatment of patients with resected stage III or high-risk stage II colon carcinoma. METHODS Patients from 330 centres in 34 countries were enrolled into this phase 3, ope...

Journal: :Investigative ophthalmology & visual science 2011
Lu Liu David A Ammar Lindsey A Ross Naresh Mandava Malik Y Kahook John F Carpenter

PURPOSE To quantify levels of subvisible particles and protein aggregates in repackaged bevacizumab obtained from compounding pharmacies, as well as in samples of bevacizumab and ranibizumab tested in controlled laboratory experiments. METHODS Repackaged bevacizumab was purchased from four external compounding pharmacies. For controlled laboratory studies, bevacizumab and placebo were drawn i...

Journal: :بینا 0
سیدمهدی مدرس زاده m modareszadeh ophthalmic research center, iran university of medical sciences, tehran, iranتهران- خیابان ستارخان- خیابان نیایش- بیمارستان حضرت رسول اکرم (ص)- مرکزتحقیقات چشم مژگان رضایی کنوی m rezaie kanavi ophthalmic research center, shahid beheshti university of medical sciences, tehran, iranدانشگاه علوم پزشکی شهید بهشتی حسین نظری h nazari ophthalmic research center, iran university of medical sciences, tehran, iranتهران- خیابان ستارخان- خیابان نیایش- بیمارستان حضرت رسول اکرم (ص)- مرکزتحقیقات چشم خلیل قاسمی فلاورجانی kh ghasemi falavarjani ophthalmic research center, iran university of medical sciences, tehran, iranتهران- خیابان ستارخان- خیابان نیایش- بیمارستان حضرت رسول اکرم (ص)- مرکزتحقیقات چشم عادل قاسم پور a ghasempoor ophthalmic research center, iran university of medical sciences, tehran, iranتهران- خیابان ستارخان- خیابان نیایش- بیمارستان حضرت رسول اکرم (ص)- مرکزتحقیقات چشم

purpose: to evaluate the safety of different doses of intravitreal bevacizumab in rabbit eyes. methods: twelve eyes of 6 rabbits underwent intravitreal injection of 5, 7.5 and 10 mg of bevacizumab. in each rabbit, one eye was considered for bevacizumab injection and the fellow eye served for either placebo injection or observation. all eyes were examined before and 1, 2, 3, 7, 14 and 28 days af...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Jun-ichiro Kuroda Jun-ichi Kuratsu Masahiro Yasunaga Yoshikatsu Koga Hirotsugu Kenmotsu Takashi Sugino Yasuhiro Matsumura

PURPOSE To clarify the effect of bevacizumab on NK012 therapy in mice bearing U87MG glioblastoma orthotopic xenografts in comparison with the combination therapy of irinotecan hydrochloride (CPT-11) with bevacizumab. EXPERIMENTAL DESIGN NK012 at 7-ethyl-10-hydroxycamptothecin (SN-38) equivalent dose of 30 mg/kg was administered intravenously three times every 4 days with or without bevacizuma...

Journal: :Investigative ophthalmology & visual science 2018
Li-Fong Seet Li Zhen Toh Stephanie Chu Sharon N Finger Florent Ginhoux Wanjin Hong Tina T Wong

Purpose We determine the effects of bevacizumab on collagen production in a mouse model of conjunctival scarring. Methods Experimental surgery was performed as described for the mouse model of conjunctival scarring, and bevacizumab was introduced by conjunctival injection. The capacity of bevacizumab to recognize conjunctival VEGF-A was determined by ELISA. Col1a1 was measured by real-time PC...

2016
Wei Xu Meng Kuang Yang Gong Chunxiang Cao Jinfei Chen Cuiju Tang

BACKGROUND The survival of patients with metastatic colorectal cancer (mCRC) could be improved with exposure to three active drugs, irinotecan, fluorouracil/leucovorin, and oxaliplatin, irrespective of their sequence. However, only 50%-80% of patients can be exposed to all the three drugs in a sequential strategy with two-drug combinations. We carried out this systematic assessment to compare t...

Journal: :Molecular cancer therapeutics 2007
Huynh Hung

Prostate cancer is the most common malignancy in men. Although patients with metastatic prostate cancer can benefit from androgen ablation, most of them will die of prostate cancer progression to an androgen-refractory state. In the present study, the effects of docetaxel, bevacizumab, 5-fluorouracil (5-FU), bevacizumab plus docetaxel, and bevacizumab plus 5-FU on the growth of human CWR-22 (an...

2017
Tao Jiang Aiwu Li Chunxia Su Xuefei Li Chao Zhao Shengxiang Ren Caicun Zhou Jun Zhang

This study aimed to investigate the role of bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) who had developed acquired resistance to EGFR-TKIs therapy that manifested as malignant pleural effusion (MPE). In total, 86 patients were included. 47 patients received bevacizumab plus continued EGFR-TKIs and 39 patients received bevacizumab plus chemotherapy. The curative effi...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Seiji Mabuchi Yoshito Terai Kenichiro Morishige Akiko Tanabe-Kimura Hiroshi Sasaki Masanori Kanemura Satoshi Tsunetoh Yoshimichi Tanaka Masahiro Sakata Robert A Burger Tadashi Kimura Masahide Ohmichi

PURPOSE Vascular endothelial growth factor (VEGF) plays a central role in tumor angiogenesis and is regarded as a promising therapeutic target. We hypothesized that treatment with bevacizumab, a humanized recombinant anti-VEGF monoclonal antibody, could enhance antitumor response to cisplatin and prolong survival in a murine ovarian cancer model. EXPERIMENTAL DESIGN We conducted an MTS assay ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید